Showing results (261-270 of 275) with videos related to

Sort By:
Pageof 28
Annals of Hematology|January 17, 2024
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumabMin Qing, Tianyuan Zhou, Tatiana Perova, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2016
Clinical Features and Survival of Patients With Follicular Lymphoma in KoreaSu-Hee Cho, Cheolwon Suh, Young Rok Do, et al.
The Lancet. Haematology|November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trialMichinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Nature Cancer|March 18, 2025
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trialWon Seog Kim, Tae Min Kim, Seok-Goo Cho, et al.
Bone Marrow Transplantation|March 4, 2024
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1Silvia Park, Su-Yeon Bang, Daehun Kwag, et al.
Cancers|July 9, 2022
Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk StratificationTong-Yoon Kim, Silvia Park, Daehun Kwag, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromesJae-Ho Yoon, Young-Woo Jeon, Seung-Ah Yahng, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2021
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III StudyLarry W Kwak, Juan-Manuel Sancho, Seok-Goo Cho, et al.
Therapeutic Advances in Hematology|March 28, 2022
A retrospective comparison of salvage intensive chemotherapy <i>versus</i> venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)Silvia Park, Daehun Kwag, Tong Yoon Kim, et al.
Leukemia & Lymphoma|August 20, 2025
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapyElżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, et al.
Pageof 28